In MIT's Technology Review, reporter Emily Singer examines new microfluidics technology from the Woburn, Mass.-based Claros Diagnostics, which can detect prostate specific antigen levels in only 15 minutes. "If approved by the US Food and Drug Administration, the device will be one of the first examples of long-awaited microfluidics-based diagnostics tests that can be performed in the hospital or doctor's office," according to Tech Review. The disposable microfluidics cartridge, about the size of a credit card, requires only a small drop of blood; the reader, comparable in size to a toaster, "could, in theory at least, be adapted to detect any number of different proteins," Singer writes. The company is currently running clinical trials — which compare the utility of its device to standard prostate specific antigen testing — and expects results within a few months. Claros hopes to launch their device in Europe later this year and in the US in 2011.
Microfluidics-based PSA Diagnostic Device Produces Rapid Results
Mar 31, 2010